Ocrelizumab
Template:Drugbox-mab
Ocrelizumab is a humanized anti CD20 monoclonal antibody. It targets mature B lymphocytes. As of May 2007 it is in clinical trials (phase III) for rheumatoid arthritis, multiple sclerosis and lupus erythematosus.
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |